Clinical Trials Browser

Phase 1 × Completed × Bexarotene × Clear all

NCT04664829 2025-09-23

The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC

Phase 1 Completed

Triple Negative Breast Neoplasms

NCT01116622 2023-10-18

Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive Tract

Phase 1 Completed

GastrointestinalHead & Neck

Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus)

NCT03323658 2023-01-10

Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer

Phase 1 Completed

24 enrolled 12 charts

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating

NCT01134341 2019-12-18

Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Phase 1 Completed

DermatologicLymphoid

Mycosis Fungoides, Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphoma, Primary Cutaneous Anaplastic Large Cell

NCT00316030 2016-06-08

Study of Bexarotene in Patients With Acute Myeloid Leukemia

Phase 1 Completed

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT01001143 2014-07-29

AML

Phase 1 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00055991 2013-02-05

Bexarotene in Preventing Breast Cancer in Women at Genetic Risk

Phase 1 Completed

Breast Neoplasms